Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • MannKind Corp. (MNKD) And Colby Pharmaceutical Sign Agreement To Develop And Commercialize Cancer Immunotherapy Products 0 comments
    Nov 13, 2012 2:48 PM | about stocks: MNKD

    MannKind is a company that focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. The company's lead product candidate, AFREZZA, is in late stage clinical trials for treatment of adults with both types of diabetes.

    The company announced today the signing of an agreement with privately-held Colby Pharmaceutical Company. The license agreement grants Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind's novel MKC1106 active immunotherapy programs. These programs are currently being developed for the treatment of melanoma, prostate, hematological disorders, and other cancers.

    Intra-lymph node injections of cancer vaccine antigens have been shown in animal testing to generate much more potent therapeutic T-cell responses, when compared to cancer vaccine antigen immunizations using traditional intra-muscular or sub-cutaneous injections. In a Phase I human melanoma study of MKC1106-MT, these injections to date have been well tolerated and have generated strong immune responses.

    Under the terms of the agreement, Colby will pay Mannkind upfront and milestone payments linked to the development, approval, and commercialization of products. It is believed these payments will be valued in total at approximately $140 million. In addition, MannKind will receive tiered royalties on the sales of the commercialized products.

    For additional information about MannKind Corporation and its product candidates, please visit www.mannkindcorp.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: MNKD
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.